COMMUNIQUÉS West-GlobeNewswire

Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
30/10/2026
MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases [...]
NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes
30/10/2026
New results strengthen the foundation for commercial naïve exosome supply and continued development of ExoPTEN TORONTO and HAIFA, Israel, Oct. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: [...]
Polk County Mosquito Control Reduces Aedes aegypti by Up to 95% with Sterile Insect Farms™ Sterile Male Releases
30/10/2026
BUFORD, Ga., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Polk County Mosquito Control has reduced populations of Aedes aegypti (its top problem species and a primary carrier of dengue, Zika, and chikungunya) by up to 95% after [...]
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
30/10/2026
Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technology Technologies will be presented at TCT 2026 in the Canon booth TUSTIN, Calif. and ST. LOUIS, [...]
Profound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
30/10/2026
New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical’s Copernicus™ program, expanding Profound’s commercial reach Profound retains direct TULSA-PRO recurring treatment kit [...]
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
30/10/2026
Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos’s R&D Facility; Data Support IND-Enabling [...]
Aer Therapeutics Announces Top-Line Results from its Phase 2a Proof-of-Concept Trial of Fexlamose in Chronic Obstructive Pulmonary Disease (“COPD”)
30/10/2026
90 mg dose of fexlamose administered daily via nebulizer did not demonstrate improvement on trough FEV1, FVC and other spirometric measures with 28 days of dosing in moderate to severe COPD patients. Fexlamose did not [...]
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
30/10/2026
Completed enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27 Expanded telitacicept franchise into ocular myasthenia gravis with Phase 3 [...]
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
30/10/2026
- Agreement complements revenue from standard gene expression and DRP® services - Development and validation services will support a European biotechnology company’s precision oncology predictive device for use in the [...]
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
30/10/2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other [...]
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
30/10/2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other [...]
Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update
30/10/2026
Highlights FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA) New U.S. composition of matter patent granted for ATH434, extending [...]
Syndax Announces Participation in November Investor Conferences
30/10/2026
NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
30/10/2026
-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
30/10/2026
Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as Safe (GRAS) by the FDA [...]
Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
30/10/2026
Patent milestones build on positive REMAIN-1 six-month pivotal results and patient research supporting interest in a one-time procedure for post-GLP-1 weight maintenance New catheter patent provides protection extending [...]
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
30/10/2026
FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease FDA classified Agios’ response to the information request as a major amendment to the mitapivat [...]
Regeneron Reports Third Quarter 2026 Financial and Operating Results
30/10/2026
Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025 Dupixent ® global net sales (recorded by Sanofi) increased 35% to $6.5 billion EYLEA HD ® U.S. net sales increased 62% to $699 million [...]
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
30/10/2026
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders [...]

Pages